tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NAMS Stock Latest News

NewAmsterdam Pharma price target raised to $50 from $42 at Citi
The FlyNewAmsterdam Pharma price target raised to $50 from $42 at Citi
2d ago
NAMS
NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials
PremiumCompany Announcements
NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials
2M ago
8K
NAMS
NewAmsterdam Pharma initiated with an Overweight at Wells Fargo
PremiumThe Fly
NewAmsterdam Pharma initiated with an Overweight at Wells Fargo
2M ago
NAMS
NewAmsterdam Pharma’s EMA Validation for Obicetrapib
PremiumCompany Announcements
NewAmsterdam Pharma’s EMA Validation for Obicetrapib
2M ago
8K
NAMS
NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib
PremiumThe Fly
NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib
2M ago
NAMS
NewAmsterdam Pharma Signs Supply Agreement with Menarini
PremiumCompany AnnouncementsNewAmsterdam Pharma Signs Supply Agreement with Menarini
2M ago
8K
NAMS
Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data
Premium
Ratings
Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data
2M ago
NAMS
NewAmsterdam Pharma Reports Q2 2025 Financial Results
Premium
Company Announcements
NewAmsterdam Pharma Reports Q2 2025 Financial Results
2M ago
NAMS
Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma
PremiumRatings
Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma
2M ago
NAMS
Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements
PremiumRatings
Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements
2M ago
NAMS
Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments
PremiumRatings
Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments
2M ago
NAMS
NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year
PremiumThe Fly
NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year
2M ago
NAMS
Buy Rating for NewAmsterdam Pharma: Promising Developments in Alzheimer’s and Cardiovascular Trials
PremiumRatingsBuy Rating for NewAmsterdam Pharma: Promising Developments in Alzheimer’s and Cardiovascular Trials
3M ago
NAMS
Promising Alzheimer’s Biomarker Data and Expert Enthusiasm Drive Buy Rating for NewAmsterdam Pharma
Premium
Ratings
Promising Alzheimer’s Biomarker Data and Expert Enthusiasm Drive Buy Rating for NewAmsterdam Pharma
3M ago
NAMS
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results
Premium
Company Announcements
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results
3M ago
8K
NAMS
NewAmsterdam Pharma presents data from BROADWAY trial at AAIC
PremiumThe Fly
NewAmsterdam Pharma presents data from BROADWAY trial at AAIC
3M ago
NAMS
NewAmsterdam Pharma initiated with a Neutral at Goldman Sachs
PremiumThe Fly
NewAmsterdam Pharma initiated with a Neutral at Goldman Sachs
3M ago
NAMS
NewAmsterdam Pharma Updates Employment Agreement with Executive
PremiumCompany Announcements
NewAmsterdam Pharma Updates Employment Agreement with Executive
3M ago
8K
NAMS
NewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald
PremiumThe Fly
NewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald
4M ago
NAMS
NewAmsterdam Pharma initiated with a Buy at Citi
PremiumThe FlyNewAmsterdam Pharma initiated with a Buy at Citi
4M ago
NAMS
Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
Premium
Ratings
Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
4M ago
NAMS
NewAmsterdam Pharma Schedules R&D Day for June 2025
Premium
Company Announcements
NewAmsterdam Pharma Schedules R&D Day for June 2025
4M ago
8K
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >